Mylan's $600 price tag for its emergency anaphylaxis treatment EpiPen (epinephrine) could spur more than probes into the company's pricing practices. It could turn into a wider investigation into industry's use of patient assistance programs.
The latest fireworks over Mylan NV's price increases on EpiPen (epinephrine) could trigger more than just an investigation into the company's pricing practices. It could turn into a wider examination of industry's use of patient assistance programs (PAPs), which already are being probed by US federal prosecutors and state attorneys general.
Mylan's $600 price tag for the emergency treatment for allergic reactions, a 500% price increase since 2009, has captured widespread...
A July white paper from Lifescience Dynamics explores the potential ways AI could see usage in pricing, reimbursement and market access for biopharma companies.
Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. The feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.
Lilly said prices governments pay in developed countries, including those in Europe, need to increase to make US drug prices lower, rebalancing costs as CEO David Ricks recently advocated.
As President Trump focuses on “most favored nation” pricing to bring down US drug costs, CEO David Ricks used Lilly’s Q2 earnings call to advocate for a slow approach to reducing the difference between US and EU drug prices.
Recent moves in the industry include an ex-Pfizer exec as the new CEO at Cha Vaccine Institute and a C-suite shuffle at Paragon Therapeutics, plus six other companies get new CFOs.
Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.
The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.
